CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Elosulfase alfa

Last Updated: August 5, 2014
Result type: Reports
Project Number: SR0389-000
Product Line: Reimbursement Review

Generic Name: Elosulfase alfa

Brand Name: Vimizim

Manufacturer: BioMarin Pharmaceutical (Canada) Inc.

Therapeutic Area: Mucopolysaccharidosis IVA (Morquio A syndrome)

Indications: Mucopolysaccharidosis IVA (Morquio A syndrome)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: March 25, 2015

Recommendation Type: Do not list